Delving into the Latest Updates on Mitotech SA with Synapse

Overview

Basic Info

Introduction

Mitotech S.A. is a biotechnology firm headquartered in Luxembourg that specializes in developing innovative drugs for the treatment of age-related disorders. Their drug pipeline includes an ophthalmic drug (Visomitin) and a systemic drug (Plastomitin) that share the same lead compound, SkQ1, which is a potent mitochondria-targeted antioxidant. The company's team consists of a diverse group of experts from various fields, including science, clinical drug development, and business management. By combining their skills and knowledge, they aim to address complex scientific issues, such as cellular oxidative stress, and turn research findings into effective pharmaceutical products. Mitotech S.A.'s ultimate goal is to provide patients worldwide with medications that utilize a novel mechanism of action and deliver highly active antioxidants to mitochondria across a broad range of age-related therapeutic indications.

Tags

Eye Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

Electron transport chain complex proteins(Electron transport chain complex proteins)	1

In a single-center, randomized, double-masked, placebo-controlled, 29-day study, 91 subjects with mild to moderate dry eye instilled the study drug twice daily and recorded dry eye symptoms daily. Subjects were randomized 1:1:1 into one of three ophthalmic solution treatment groups: SkQ1 1.55 µg/mL, SkQ1 0.155 µg/mL, or 0.0 µg/mL (placebo). Subjects were exposed to a controlled adverse environment chamber at 3 of the 4 study visits (Day -7, Day 1, and Day 29). Investigator assessments occurred at all study visits.

RESULTS:

SkQ1 was safe and efficacious in treating dry eye signs and symptoms. Statistically significant improvements with SkQ1 compared to placebo occurred for the dry eye signs of corneal fluorescein staining and lissamine green staining in the central region and lid margin redness, and for the dry eye symptoms of ocular discomfort, dryness, and grittiness. In addition, SkQ1 demonstrated greater efficacy compared to placebo, although the differences were not statistically significant, for corneal fluorescein staining in other regions and/or time points (total staining score, central region, corneal sum score, and temporal region), lissamine green staining for the central and nasal regions, and blink rate scores.

CONCLUSIONS:

This Phase 2 study indicated that SkQ1 is safe and efficacious for the treatment of dry eye signs and symptoms and supported previous study results.

TRIAL REGISTRATION:

Clinicaltrials.gov identifier: NCT02121301.

FUNDING:

Miotech S.A.

100 Deals associated with Mitotech SA

Login to view more data

100 Translational Medicine associated with Mitotech SA

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 Jul 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Approved

Login to view more data